Interim Monitoring Visit (IMV)

Interim Monitoring Visit (IMV) - Axcellant

Interim Monitoring Visit (IMV)

  1. Feb 28, 2025

What Does the ‘Interim Monitoring Visit (IMV)’ Mean?

An Interim Monitoring Visit (IMV) is a scheduled on-site evaluation conducted during the course of a clinical trial. It is performed by a clinical research associate or monitor to assess the progress of the study, ensure compliance with protocols, and verify the accuracy and completeness of data collected.

IMVs are crucial for maintaining the quality and integrity of clinical research. During these visits, monitors review source documents, case report forms, and other study-related materials to identify and address any issues or discrepancies that may have arisen since the previous visit.

Why Is the ‘Interim Monitoring Visit (IMV)’ Important in Clinical Research?

Interim Monitoring Visits are essential for ensuring the ongoing quality and integrity of clinical trials. These visits allow for timely identification and correction of protocol deviations, data discrepancies, and other issues that could potentially compromise the validity of study results.

IMVs also play a crucial role in protecting the rights and safety of study participants. By regularly verifying adherence to ethical guidelines and regulatory requirements, these visits help maintain the highest standards of patient care and data management throughout the duration of a clinical trial.

Good Practices and Procedures

  1. Establish a standardized checklist tailored to the specific study protocol, including key areas such as informed consent, eligibility criteria, and adverse event reporting.
  2. Implement a risk-based monitoring approach, allocating more time and resources to critical data points and high-risk areas identified during previous visits or data reviews.
  3. Conduct targeted source data verification, focusing on a predetermined percentage of data points rather than 100% verification, to improve efficiency without compromising data integrity.
  4. Schedule debriefing sessions with key site personnel at the conclusion of each IMV to discuss findings, address concerns, and collaboratively develop action plans for improvement.
  5. Utilize electronic data capture systems and remote monitoring technologies to supplement on-site visits, enabling continuous oversight and reducing the frequency of in-person IMVs when appropriate.

Related Terms

Resources

Large Language Models in Nuclear Cardiology: From Experimental Tools to Clinical Infrastructure

3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…

From Half-Life to Clinical Impact: Mastering Time-Critical Supply Chains

How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…

How ACT EU Is Forcing a Global Approach to Trial Timelines

Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…